Реальные и потенциальные преимущества антагониста кальция III поколения лерканидипина
Аннотация
Об авторе
А. А. КириченкоРоссия
Список литературы
1. Leenen F.H.H. Clinical relevance of 24 hour blood pressure control by 1,4-dihydropyridines. Am J Hypertens 1996; 9: S97–S104.
2. Epstein M. Role of a third generation calcium antagonists in the management of hypertension. Drugs 1999; 57 (Suppl. 1): 1–10.
3. McClellan K.J., Jarvis B. Lercanidipine. A review of its use in hypertension. Drugs 2000; 60 (5): 1123–40.
4. Van Zweiten P.A., Pfaffendorf M. Similarities and differences between calcium antagonists: Pharmacological aspects. J Hypertens 1993; 11 (Suppl. 1): S3–S11.
5. Van Zweiten P.A., Pfaffendorf M. Pharmacology of dihydropyridine calcium antagonists; Relatiomship between lipophilicity and pharmacodynamic response. J Hypertens 1993; 11 (Suppl. 6): S3–S11.
6. Sranchez M, Sobrino J, Ribera L. et al. Long - acting lacidipine versus short - acting nifedipine in the treatment of asymptomatic acute blood pressure increase. J Cardiovasc Pharmacol 1999; 33: 479–84.
7. Heber M.E., Broadhurst P.A., Bridgen G.S. et al. Effectiveness of the once - daily calcium antagonists, lacidipine, in controlling 24-hour ambulatory blood pressure. Am J Cardiol 1990; 66: 1228–32.
8. Gasser R, Koppel H, Klein W. Lercanidipine, a new third generation Ca - antagonist in the treatment of hypertension. J Clin Basic Cardiol 1999; 2: 169–74.
9. Leonardi A, Poggesi E, Tiiddei C et al. In vitro calcium antagonist activity of lercanidipine and its enantiomers. J Cardiovasc Pharmacol 1997; 29 (Suppl.1): S10–S18.
10. Triggle D.J. Mechanisms of action of calcium channel antagonists. In: Calcium antagonists in clinical medicine. Ed. by M.Epstein. Philadelphia, 1998: pp. 1–26.
11. Nayler W.G. Amlodipine. Berlin, 1995: p. 1–273.
12. Herbette L.G., Vecchiarelli M, Leonardi A. Lercanidipine: Short plasma half - life, long duration of action. J Cardiovascul Pharmacol 1997; 29 (Suppl.1): S19–S24.
13. Herbette L.G., Gaviraghi G, Tulenko T. et al. Molecular interaction between lacidipine and biological membranes. J Hypertens 1993; 11 (Suppl. 1): S13–S19.
14. Ahernethy D.R., Schwartz J.B. Calcium - antagonist drugs. N Engl J Med 1999; 341: 1447–57.
15. Specchia G, Saccaggi S.P., Ghezzi C. Cardiovascular safety of lercanidipine in patients with angina pectoris: a review of six randomized clinical trials. Curr Ther Res 2001; 62: 3–15.
16. Angelico P, Guarneri L, Leonardi A. et al. Vascular - selective effect of lercanidipine and other 1,4-dihydropyridines in isolated rabbit tissues. J Pharm Pharmacol 1999; 51: 709–14.
17. Policicchio D, Magliocca R, Malliani A. Efficacy and tolerability of lercanidipine in patients with mild to moderate essential hypertension: a comparative study with slow - release nifedipine. J Cardiovasc Pharmacol 1997; 29 (Suppl. 2): S31–5.
18. Leonetti G, Salvi S. A long - term study comparing lacidipine and nifedipine SR in hypertensive patients: safety data. J Cardiovasc Pharmacol 1994; 23 (Suppl. 5): S108–S110.
19. Lombardo D, Raimondi F. Efficacy and safety evaluation of lacidipine compared with amlodipine in mild - to - moderate hypertensive patients. J Cardiovasc Pharmacol 1994; 23 (Suppl. 5): S98–S100.
20. United Kingdom Lacidipine Study Group. A double - blind comparison of the efficacy and safety of lacidipine with atenolol in the treatment of essential hypertension. J Cardiovasc Pharmacol 1991; 17 (Suppl. 4): S27–S30.
21. Guedon J, Herrero G, Salvi S. Assessment of lacidipine, a new long - acting 1,4 dihydropyridine calcium antagonist, for the primary care of elderly hypertensive patients. Cardiol Eld 1993; 1: 141–8.
22. Romito R, Pansini M.I., Perticone F. et al. Comparative effect of lercandipine, felodipine and nifedipine GITS on blood pressure and heart rate in patients with mild to moderate arterial hypertension: the Lercandipine in Adults (LEAD) study. J Clin Hypertens 2003; 5 (4): 249–53.
23. Cavallini A, Terzi G. Effects of antihypertensive therapy with lercanidipine and verapamil on cardiac electrical activity in patients with hypertension: a randomized, double - blind pilot study. Curr Ther Res 2000; 61 (7): 477–87.
24. Packer M, O'Connor M, Ghali J.K. et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 1996; 335: 1107–14.
25. Barbagallo M, Barbagallo Sangiorgi G. Efficacy and tolerability of lercanidipine in monotherapy in elderly patients with isolated systolic hypertension. Aging Clin Exp Res 2000; 12 (5): 375–9.
26. Kizer I.R., Kimmel S.E. Epidemiologic review of calcium channel blocker drugs. Arch Intern Med 2001; 161: 1145–58.
27. Fogari R, Mugellini A, Corradi L et al. Efficacy of lercanidipine vs losartan on left ventricular hypertrophy in hypertensive type 2 diabetic patients [abstract no. P1.191]. J Hypertens 2000; 18 (Suppl. 2): S65.
28. S’anchez A, Sayans R, Alvarez J.L. et al. Left ventricular hypertrophy regression after a short antihypertensive treatment with lercanidipine vs. enalapril [abstract no. 12]. Fourth European Meeting on Calcium Antagonists, 1999, оct 27–29. Amsterdam.
29. Peterson J.E., Adler S, Burkart L.M. et al. Blood pressure control, proteinuria and the progression of renal disease: the odification of diet in renal disease study. Ann Intern Med 1995; 123: 754–62.
30. Toto R.D., Mitchell N.C., Smith R.O. «Strict» blood pressure control and progression of renal disease in hypertensive ephrosclerosis. Kidney Int 1995; 48: 851–9.
31. Gansevoort R.T., Sluiter W.J., Hemrnelder M.H. et al. Antiproteinuric effect of blood pressure lowering agents: a metaanalysis of comparative trials. Nephrol Dial Transplant 1995; 10: 1963–74.
32. Pedrinelli R, Dell’Omo G, Nuti M et al. Heterogenous effect of calcium antagonists on leg oedema: a comparison of amlodipine versus lercanidipine in hypertensive patients. J Hypertens 2003; 21: 1969–73.
33. Cavallini A, Terzi G. Effects of antihypertensive therapy with lercanidipine and verapamil on cardiac electrical activity in patients with hypertension: a randomized, double - blind pilot study. Curr Ther Res 2000; 61 (7): 477–87.
34. Macchiarulo C, Pieri R, Mitolo D.C. et al. Antihypertensive effects of six calcium antagonists: evidence from Fourier analysis of 24-hour ambulatory blood pressure recordings. Curr Ther Res 2001; 62 (4): 236–53.
35. Fogari R, Malamani G.D., Zoppi A. et al. Comparative effect of lercanidipine and nifedipine gastrointestinal therapeutic system on ankle volume and subcutaneous interstitial pressure in hypertensive patients: a double - blind, randomized, parallel group study. Curr Ther Res Clin Exp 2000; 61: 850–62.
36. Paterna S, Licata A, Arnone S et al. Lercanidipine in two different dosage regimens as a sole treatment for severe essential hypertension. J Cardiovasc Pharmacol 1997; 29 (Suppl. 2): S50–3.
37. Barbagallo M, Barbagallo Sangiorgi G. Efficacy and tolerability of lercanidipine in monotherapy in elderly patients with isolated systolic hypertension. Aging Clin Exp Res 2000; 12 (5): 375–9.
38. Brown M.J., Palmer C.R., Castaigne A. et al. Morbidity and mortality in patients randomized to double - blind treatment with a long - acting calcium - channel blocker or diuretic in the international nifedipine GITS study: intervention as a goal in hypertension treatment (INSIGHT). Lancet 2000; 356: 366–72.
39. Lewis E, Huncksicker L.G., Clarke W.R. et al. Renoprotective effect of the angiotensinreceptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851–60.
40. Parving III-I, Lehnert I-I, Brochner-Mortenscn I. et al. For the study group Irbesartun in patients with type 2 diabetes and microalbumlnuria. N Engl J Med 2001; 345: 870–8.
41. Agodoa L.Y., Appel L, Bakris G.L. et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 2001; 285: 2719–28.
42. Epstein M. Calcium antagonists and renal protection: emerging perspectives. J Hypertens 1998; J8 (Suppl. 4): S17–25.
43. Sabbatini M, Leonardi A, Testa R et al. Effect of calcium antagonists on glomerular arterioles in spontaneously hypertensive rats. Hypertension 2000; 35: 775–9.
44. Bakris G.L., Weir M.R., De Quattro V. et al. The effects of an ACE inhibitor and a calcium antagonists on the progression of renal disease: the nephross study. Nephrol Dial Transplant 2001; J6: 2158–66.
45. Robles N.R., Ocon J, Gomez C.F. et al. Лерканидипин у пациентов с хронической почечной недостаточностью: исследование ZAFRA. Кардиоваскулярная терапия и профилактика. 2010; 9 (4): 81–7.
46. Soma M.R., Natali M, Donetti E. et al. Effect of lercanidipine its (R)-enantiomer on atherosclerotic lesions induced in hypercholesterolemic rabbits. Br J Pharmacol 1998; 125: 1471–6.
47. Lozano J.V., Sanchis C, Llisterri J.L. Efficacy of lercanidipine in poorly controlled hypertensive patients who follow a home blood pressure measurement training program [abstract no. R190]. J Hypertens 2002; 20 (Suppl. 4): S376.
48. Barrios V, Navarro A, Esteras A et al. Antihypertensive efficacy and tolerability of lercanidipine in daily clinical practice. The ELYPSE study. Blood Press 2002; 11 (2): 95–100.
49. Schwinger R.H.G, Schmidt-Mertens A. The new lipophillic calcium channel blocker lercanidipine combines high antihypertensive efficacy with low side effects [abstract no. P1–7]. Dtsch Med Wochenschr 2002; 127 (Suppl. 1): S13.
50. Romito R, Pansini M.I., Perticone F. et al. Comparative effect of lercanidipine, felodipine and nifedipine GITS on blood pressure and heart rate in patients with mild to moderate arterial hypertension: the Lercandipine in Adults (LEAD) study. J Clin Hypertens 2003; 5 (4): 249–53.
51. Morisco C, Trimarco B. Efficacy and tolerability of lercanidipine in comparison to and in combination with atenolol in patients with mild to moderate hypertension in a double blind controlled study. J Cardiovasc Pharmacol 1997; 29 (Suppl. 2): S26–30.
52. Barbagallo M, Barbagallo Sangiorgi G. Efficacy and tolerability of lercanidipine in monotherapy in elderly patients with isolated systolic hypertension. Aging Clin Exp Res 2000; 12 (5): 375–9.
53. Acanfora D, Gheorgiade M, Rotiroti D. et al. Acute dose - response, double - blind, placebo - controlled pilot study of Iercanidipine in patients with angina pectoris. Curr Ther Res 2000; 61: 255–65.
54. Leonetti G, Magnani B, Pessina A.C. et al. Tolerability of longterm treatment with lercanidipine versus amlodipine and lacidipine in elderly hypertensives. Am J Hypertens 2002; 15 (11): 932–40.
55. Borghi C, Prandin M.G., Dormi A. et al. Improved tolerability of the dihydropyridine calcium - channel antagonist lercanidipine: the lercanidipine challenge trial. Blood Press 2003; 12 (Suppl. 1): 1–8.
Рецензия
Для цитирования:
Кириченко А.А. Реальные и потенциальные преимущества антагониста кальция III поколения лерканидипина. Системные гипертензии. 2013;(1):57-61.
For citation:
Kirichenko A.A. Real and potential benefits of third-generation calcium antagonists. Systemic Hypertension. 2013;(1):57-61.